Paper465283
Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.
Finch RE and 2 others. Br J Clin Pharmacol, 1979. Cited by 56 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Papers, record 465283. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/465283
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fluorouracil | Major topic |
| Neoplasms | Major topic |
| Administration, Oral | |
| Adult | |
| Aged | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Injections, Intravenous | |
| Kinetics | |
| Male | |
| Middle Aged |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14,217,470 | A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE. | JAMA | 1964 | https://conductscience.org/library/papers/14217470 | PubMed |
| 2 | 14,070,379 | EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY. | Cancer Res | 1963 | https://conductscience.org/library/papers/14070379 | PubMed |
| 3 | 78,795 | Antineoplastic drugs: clinical pharmacology and therapeutic use. | Drugs | 1978 | https://conductscience.org/library/papers/78795 | PubMed |
| 4 | 69,319 | Clinical pharmacology of anticancer drugs. | Semin Oncol | 1977 | https://conductscience.org/library/papers/69319 | PubMed |
| 5 | 350,471 | Why monitor serum levels of gentamicin? | Clin Pharmacokinet | 1978 | https://conductscience.org/library/papers/350471 | PubMed |
| 6 | 336,866 | Kinetics and mechanisms of drug action of microorganisms XXIII: microbial kinetic assay for fluorouracil in biological fluids and its application to human pharmacokinetics. | J Pharm Sci | 1977 | https://conductscience.org/library/papers/336866 | PubMed |
| 7 | 302,412 | Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. | N Engl J Med | 1977 | https://conductscience.org/library/papers/302412 | PubMed |
| 8 | 702,315 | Use of a nitrogen detector for GLC determination of fluorouracil in plasma during single- and combined-agent chemotherapy. | J Pharm Sci | 1978 | https://conductscience.org/library/papers/702315 | PubMed |
| 9 | 678,346 | Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. | Clin Pharmacokinet | 1978 | https://conductscience.org/library/papers/678346 | PubMed |
| 10 | 666,946 | Plasma concentrations of isosorbide dinitrate and its metabolites after chronic high oral dosage in man. | Br J Clin Pharmacol | 1978 | https://conductscience.org/library/papers/666946 | PubMed |
| 11 | 639,472 | Changes in absorptive and peptide hydrolase activities in rat small intestine after administration of 5-fluorouracil. | Clin Sci Mol Med | 1978 | https://conductscience.org/library/papers/639472 | PubMed |
| 12 | 589,882 | Pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in monitoring therapy. | Clin Pharmacokinet | 1977 | https://conductscience.org/library/papers/589882 | PubMed |
| 13 | 4,304,025 | Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors. | Cancer | 1969 | https://conductscience.org/library/papers/4304025 | PubMed |
| 14 | 4,264,581 | 5-Fluorouracil in the treatment of gastrointestinal neoplasia. | N Engl J Med | 1973 | https://conductscience.org/library/papers/4264581 | PubMed |
| 15 | 4,259,631 | The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia. | Cancer Res | 1972 | https://conductscience.org/library/papers/4259631 | PubMed |
| 16 | 4,609,602 | Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). | Cancer Chemother Rep | 1974 | https://conductscience.org/library/papers/4609602 | PubMed |
| 17 | 4,810,089 | The administration of 5-fluorouracil by mouth. | Cancer | 1974 | https://conductscience.org/library/papers/4810089 | PubMed |
| 18 | 1,097,091 | Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. | Cancer Chemother Rep | 1975 | https://conductscience.org/library/papers/1097091 | PubMed |
| 19 | 1,203,840 | Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. | Cancer | 1975 | https://conductscience.org/library/papers/1203840 | PubMed |
| 20 | 5,144,521 | Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime. | Br J Cancer | 1971 | https://conductscience.org/library/papers/5144521 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,430,472 | 5-Fluorouracil Toxicity: Revisiting the Relevance of Pharmacokinetic Parameters. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40430472 | PubMed |
| 26,247,632 | Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. | Oncotarget | 2015 | https://conductscience.org/library/papers/26247632 | PubMed |
| 25,317,186 | Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals. | Iran J Pharm Res | 2012 | https://conductscience.org/library/papers/25317186 | PubMed |
| 25,301,172 | Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. | Cancer Gene Ther | 2014 | https://conductscience.org/library/papers/25301172 | PubMed |
| 18,846,242 | DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. | Pak J Med Sci | 2007 | https://conductscience.org/library/papers/18846242 | PubMed |
| 11,081,572 | Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil. | Invest New Drugs | 2000 | https://conductscience.org/library/papers/11081572 | PubMed |
| 11,081,567 | 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. | Invest New Drugs | 2000 | https://conductscience.org/library/papers/11081567 | PubMed |
| 10,958,591 | The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. | Invest New Drugs | 2000 | https://conductscience.org/library/papers/10958591 | PubMed |
| 8,248,211 | 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. | Proc Natl Acad Sci U S A | 1993 | https://conductscience.org/library/papers/8248211 | PubMed |
| 7,840,584 | In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/7840584 | PubMed |
| 7,160,054 | Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7160054 | PubMed |
| 6,639,003 | 5-fluorocytosine susceptibility of pathogenic fungi in the presence of allopurinol: potential for improving the therapeutic index of 5-fluorocytosine. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6639003 | PubMed |
| 6,487,480 | The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. | Br J Clin Pharmacol | 1984 | https://conductscience.org/library/papers/6487480 | PubMed |
| 3,729,334 | Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. | Antimicrob Agents Chemother | 1986 | https://conductscience.org/library/papers/3729334 | PubMed |
| 3,609,119 | Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. | Eur J Clin Pharmacol | 1987 | https://conductscience.org/library/papers/3609119 | PubMed |
| 3,445,826 | Suppression of in vitro peripheral blood lymphocyte mitogenesis by cytotoxic drugs commonly used in the treatment of breast cancer: a comparative study. | Agents Actions | 1987 | https://conductscience.org/library/papers/3445826 | PubMed |
| 2,656,050 | Clinical pharmacology of 5-fluorouracil. | Clin Pharmacokinet | 1989 | https://conductscience.org/library/papers/2656050 | PubMed |
| 1,794,023 | Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer. | Drugs Aging | 1991 | https://conductscience.org/library/papers/1794023 | PubMed |
| 533,583 | Kinetics of 5-fluorouracil. | Br J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/533583 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/465283
GET https://conductscience.org/api/papers/v1/465283/references?page=2